ClinicalTrials.gg
RecruitingNCT06891456ASCEND-VTUpdated Sep 3, 2026

Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia

An interventional study of RFA Ablation and PFA Ablation in Ventricular Tachycardia, Ischemic Heart Disease and Sustained VT, sponsored by Pasquale Santangeli. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Pasquale Santangeli · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 154 studies in Tachycardia, Ventricular with a site in United States — 34 open to participants now, 40 under way, 2 of them phase 3. Tachycardia, Ventricular · United States.

Planned enrollment
63rd of 107
40 · median 60
Started
2025
with 6 others
No phase
68 of 154
18 open now
Primary completion
2028-12
later than 31 of 39 live
Registered
146th of 154
by date

Among the 154 studies in Tachycardia, Ventricular with a site in United States, this one is the 63rd largest by planned enrollment of the 107 interventional ones that give a count, is one of 7 that started in 2025, is one of 68 with no phase, reaches primary completion later than 31 of the 39 other live ones, and was the 146th registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

34 of the 154 studies in Tachycardia, Ventricular with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Tachycardia, Ventricular with a site in United States, or all of them as a file.
02

Study summary

ASCEND is a randomized controlled open-label pilot study evaluating the safety and effectiveness of pulsed field ablation (PFA) with the novel FARAPOINT catheter compared to the standard radiofrequency (RFA) ablation with ThermoCool ST/FlexAbility SE/ThermoCool ST SF/TactiFlex SE of ventricular tachycardia (VT) in the patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator (ICD). The study hypothesis is that the PFA ablation is more efficient compared to the RFA technique but retains a comparable safety profile.

Read the detailed description

The ASCEND trial is a pilot study that will test the hypothesis that the novel FARAPOINT catheter and the FARAPULSE PFA platform can accomplish ischemic substrate VT ablation more efficiently and with a similar safety profile compared to a contemporary, widely adopted RFA technology (ThermoCool ST/FlexAbility SE/ThermoCool ST SF/TactiFlex SE).

ASCEND is a single center, controlled (two-arm), 1:1 parallel-randomized, open-label pilot study of 40 consecutively enrolled patients with ischemic cardiomyopathy and drug refractory or drug intolerant VT in whom a catheter ablation procedure is indicated. The study intervention consists of the use of a novel FARAPOINT PFA catheter during the entire VT ablation procedure. Patients randomized to the control arm of the study will undergo VT ablation using a contemporary standard-of-care technology (ThermoCool ST/FlexAbility SE/ThermoCool ST SF/TactiFlex SEcatheters).

This pilot study is designed to test for superiority with respect to the primary efficacy metric and to ensure comparable safety profiles of both ablation methods.

03

Conditions studied

  • Ventricular Tachycardia
  • Ischemic Heart Disease
  • Sustained VT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: must meet all of the following:

  1. Age ≥18 years.
  2. Ischemic heart disease with prior myocardial infarction.
  3. ≥20% estimated by transthoracic echocardiography (TTE) within 90 days prior to enrollment.
  4. Documented sustained monomorphic VT with any of the following characteristics:

    1. ≥2documented episodes in patients with implantable cardioverter defibrillators (ICD)
    2. ≥1 documented episode(s) in patients without ICD
    3. Recurrent VT despite antiarrhythmic medications (ineffective, or not tolerated) or ICD interventions
  5. Provision of signed and dated form.
  6. Stated willingness to comply with all study procedures and availability for the duration of the study.

Exclusion Criteria: any of the following:

  1. Unable to provide informed consent.
  2. Idiopathic VT.
  3. Mobile LV thrombus.
  4. Acute coronary syndrome within the preceding 2 months (if incessant VT ≥1 month before enrollment).
  5. Comorbidity likely to limit survival to \<12 months
  6. class IV heart failure.
  7. Estimated \<30 ml/min/1.73m2.
  8. Thrombocytopenia or coagulopathy.
  9. Contraindication to heparin.
  10. Pregnancy or lactation.
  11. Cardiac surgery within the past 2 months.
  12. Active infection.
  13. Clinical, laboratory or imaging evidence of active ischemia.
  14. Severe left heart valvular heart disease (aortic/mitral stenosis or regurgitation).
  15. Any concomitant congenital heart disease.
  16. Prior catheter or surgical ablation of VT within the past 2 months.
  17. Anticipated need for epicardial mapping and ablation.
  18. For individuals with no pre-existing ICD: Ineligibility for an ICD implant.
  19. Pre-existing LVAD or other hemodynamic assist device
  20. Present mechanical heart valve
  21. cardiogenic shock unless it is due to incessant VT
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    RFA Ablation

    VT ablation with ThermoCool ST, FlexAbility SE, ThermoCool ST SF or TactiFlex SE catheters

    Device: RFA Ablation

  • Experimental
    PFA Ablation

    VT ablation with FARAPOINT catheter

    Device: PFA Ablation

Interventions

  • DeviceRFA Ablation

    RFA ablation of VT substrate using FlexAbility or ThermoCool ST catheter

  • DevicePFA Ablation

    PFA ablation of VT substrate using FARAPOINT catheter

06

What researchers measure

Primary outcomes

  1. Procedural Efficiency

    Total ablation time (in seconds) needed to achieve complete elimination of late abnormal ventricular activities (LAVAs) in myocardial scar.

    Time frame: Periprocedural

  2. Procedural Safety

    Count of individuals who experience any of the following: * Cardiac perforation * Pericardial effusion with hemodynamic compromise or needing intervention * New complete heart block * Coronary spasm * Acute MI * New acute severe mitral regurgitation or aortic regurgitation * Deep venous thrombosis * Vascular injury requiring surgical or percutaneous intervention * Pulmonary embolism * Stroke * Acute kidney injury * Death

    Time frame: Within 7 days post procedure

Secondary outcomes

  1. Secondary Safety

    Changes in LVEF and/or new wall motion abnormalities at follow-up TTE

    Time frame: 180 days post procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2028, 42 months after the start.

Of 86 non-industry interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 70. This study's planned 42 months is above that.

Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Mar 24, 2025
StartActual
Jun 16, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06891456
Lead sponsor
Pasquale Santangeli
Responsible party
Pasquale Santangeli (Sponsor-Investigator, The Cleveland Clinic) — Sponsor-investigator
First posted
Mar 24, 2025
Start date
Jun 16, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 3, 2026

Study contacts

Pasquale Santangeli, MD, PhD
Contact
santanp3@ccf.org
216-445-1940
Yuki Kuramochi, BSN, RN
Contact
kuramoy@ccf.org
216-445-4063
Pasquale Santangeli, MD, PhD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion